Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, April 25, 2024 | Back issues
Courthouse News Service Courthouse News Service

Pharma Bribes

Boston-based Alexion Pharmaceuticals will pay $21.5 million to settle charges of bribing officials in Turkey and Russia to get favorable treatment for its primary drug, Soliris, which treats a blood disease, the SEC said Thursday.

WASHINGTON — Boston-based Alexion Pharmaceuticals agreed Thursday to pay $21.5 million to settle SEC charges of bribing officials in Turkey and Russia to get favorable treatment for its primary drug, Soliris, which treats a blood disease.

Categories / Business, International, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...